Inhibition of peroxisome proliferator-activated receptor gamma activity in esophageal carcinoma cells results in a drastic decrease of invasive properties

Cancer Science

Volumn 97, Issue 9, 2006, Pages 854-860

  Takahashi, Hirokazu ^a   Fujita, Kouji ^a   Fujisawa, Toshio ^a   Yonemitsu, Kyoko ^a   Tomimoto, Ayako ^a   Ikeda, Ikuko ^a   Yoneda, Masato ^a   Masuda, Tomotaka ^b   Schaefer, Katherine ^c   Saubermann, Lawrence J ^c   Shimamura, Takeshi ^a   Saitoh, Satoru ^a   Tachibana, Masashi ^d   Wada, Koichiro ^b   Nakagama, Hitoshi ^d   Nakajima, Atsushi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITRO N (4 PYRIDYL)BENZAMIDE; 2 CHLORO 5 NITROBENZANILIDE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; ESOPHAGUS CANCER; GENE TARGETING; HUMAN; HUMAN CELL; MORPHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

ACTINS; ANILIDES; APOPTOSIS; BENZAMIDES; BLOTTING, WESTERN; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION PROTEIN-TYROSINE KINASES; HUMANS; NEOPLASM INVASIVENESS; PHOSPHORYLATION; PPAR GAMMA; PYRIDINES;

EID: 33746625067     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2006.00250.x     Document Type: Article

References (32)

1. Blazeby JM, Alderson D, Farndon JR. Quality of life in patients with oesophageal cancer. Recent Results Cancer Res 2000; 155: 193-204.
2. Takashima T, Fujiwara Y, Higuchi K et al. PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 2001; 19: 465-71.
3. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res 2000; 60: 1129-38.
4. DuBois RN, Gupta R, Brockman J, Reddy BS, Krakow SL, Lazar MA. The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers. Carcinogenesis 1998; 19: 49-53.
5. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
6. Mueller E, Sarraf P, Tontonoz P et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998; 1: 465-70.
7. Sato H, Ishihara S, Kawashima K et al. Expression of peroxisome proliferator-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000; 83: 1394-400.
8. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999; 1: 330-9.
9. Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y. Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res 1999; 90: 75-80.
10. Debrock G, Vanhentenrijk V, Sciot R, Debiec-Rychter M, Oyen R, Van Oosterom A. A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 2003; 89: 1409-12.
11. Kulke MH, Demetri GD, Sharpless NE et al. A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer. Cancer J 2002; 8: 395-9.
12. Hashimoto Y, Shimada Y, Itami A et al. Growth inhibition through activation of peroxisome proliferator-activated receptor gamma in human oesophageal squamous cell carcinoma. Eur J Cancer 2003; 39: 2239-46.
13. Fujii D, Yoshida K, Tanabe K, Hihara J, Toge T. The ligands of peroxisome proliferator-activated receptor (PPAR) gamma inhibit growth of human esophageal carcinoma cells through induction of apoptosis and cell cycle arrest. Anticancer Res 2004; 24: 1409-16.
14. Rumi MA, Sato H, Ishihara S, Ortega C, Kadowaki Y, Kinoshita Y. Growth inhibition of esophageal squamous carcinoma cells by peroxisome proliferator-activated receptor-gamma ligands. J Lab Clin Med 2002; 140: 17-26.
15. Martelli ML, Iuliano R, Le Pera I et al. Inhibitory effects of peroxisome poliferator-activated receptor gamma on thyroid carcinoma cell growth. J Clin Endocrinol Metab 2002; 87: 4728-35.
16. Panigrahy D, Shen LQ, Kieran MW, Kaipainen A. Therapeutic potential of thiazolidinediones as anticancer agents. Expert Opin Invest Drugs 2003; 12: 1925-37.
17. Posch MG, Zang C, Mueller W et al. Somatic mutations in peroxisome proliferator-activated receptor-gamma are rare events in human cancer cells. Med Sci Monit 2004; 10: BR250-254.
18. Lefebvre AM, Chen I, Desreumaux P et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med 1998; 4: 1053-7.
19. Saez E, Tontonoz P, Nelson MC et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998; 4: 1058-61.
20. Schaefer KL, Wada K, Takahashi H et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. Cancer Res 2005; 65: 2251-9.
21. Masuda T, Wada K, Nakajima A et al. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. Clin Cancer Res 2005; 11: 4012-21.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Meth 1983; 65: 55-63.
23. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999; 285: 1028-32.
24. Eibl G, Wente MN, Reber HA, Hines OJ. Peroxisome proliferator-activated receptor gamma induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 2001; 287: 522-9.
25. Ohta K, Endo T, Haraguchi K, Hershman JM, Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001; 86: 2170-7.
26. Shimada T, Kojima K, Yoshiura K, Hiraishi H, Terano A. Characteristics of the peroxisome proliferator activated receptor gamma (PPARgamma) ligand induced apoptosis in colon cancer cells. Gut 2002; 50: 658-64.
27. Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL. Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 1995; 270: 16995-9.
28. Sieg DJ, Hauck CR, Ilic D et al. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000; 2: 249-56.
29. Schaller MD. Biochemical signals and biological responses elicited by the focal adhesion kinase. Biochim Biophys Acta 2001; 1540: 1-21.
30. Agochiya M, Brunton VG, Owens DW et al. Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells. Oncogene 1999; 18: 5646-53.
31. Owens LV, Xu L, Dent GA et al. Focal adhesion kinase as a marker of invasive potential in differentiated human thyroid cancer. Ann Surg Oncol 1996; 3: 100-5.
32. Yamauchi T, Waki H, Kamon J et al. Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001; 108: 1001-13.